Ali Raza
No más puestos en curso
Historial de carrera de Ali Raza
Antiguos cargos conocidos de Ali Raza.
| Empresas | Cargo | Inicio | Fin |
|---|---|---|---|
Sosei Co. Ltd.
 Sosei Co. Ltd. Miscellaneous Commercial ServicesCommercial Services Part of Sosei Group Corp., Sosei Co. Ltd. is a world-leader in GPCR medicine design and development. The company is based in Tokyo, Japan. The Japanese company obtains and maintains intellectual property rights to protect its innovations and technologies. | Director/Miembro de la Junta | 18/01/2011 | - |
| Presidente | - | - | |
| ASTRAZENECA PLC | Director Técnico/Científico/I+D | - | - |
| Corporate Officer/Principal | - | 16/02/2011 | |
YM BioSciences, Inc.
 YM BioSciences, Inc. Pharmaceuticals: MajorHealth Technology YM BioSciences, Inc. operates as a drug development company, which manufactures advancing hematology and cancer-related products. It is currently advancing in late-stage products, which include CYT387, an oral small molecule inhibitor of the kinase enzymes JAK1 and JAK2; and Nimotuzumab, an EGFR targeting humanized monoclonal antibody. The company was founded in 1994 and is headquartered in Mississauga, Canada. | Corporate Officer/Principal | 01/06/2008 | - |
Formación de Ali Raza.
| The University of Manchester | Undergraduate Degree |
| University of London | Doctorate Degree |
Estadísticas
Internacional
| Reino Unido | 5 |
| Japón | 2 |
Operativa
| Corporate Officer/Principal | 2 |
| Director/Board Member | 1 |
| President | 1 |
Sectorial
| Health Technology | 3 |
| Consumer Services | 3 |
| Commercial Services | 2 |
Funciones ocupadas
Activas
Inactivas
Empresas cotizadas
Empresas privadas
Empresas relacionadas
| Empresas cotizadas | 1 |
|---|---|
| ASTRAZENECA PLC | Health Technology |
| Empresas privadas | 2 |
|---|---|
YM BioSciences, Inc.
YM BioSciences, Inc. Pharmaceuticals: MajorHealth Technology YM BioSciences, Inc. operates as a drug development company, which manufactures advancing hematology and cancer-related products. It is currently advancing in late-stage products, which include CYT387, an oral small molecule inhibitor of the kinase enzymes JAK1 and JAK2; and Nimotuzumab, an EGFR targeting humanized monoclonal antibody. The company was founded in 1994 and is headquartered in Mississauga, Canada. | Health Technology |
Sosei Co. Ltd.
Sosei Co. Ltd. Miscellaneous Commercial ServicesCommercial Services Part of Sosei Group Corp., Sosei Co. Ltd. is a world-leader in GPCR medicine design and development. The company is based in Tokyo, Japan. The Japanese company obtains and maintains intellectual property rights to protect its innovations and technologies. | Commercial Services |
- Bolsa de valores
- Insiders
- Ali Raza
- Experiencia
